European equities traded in the US as American depositary receipts were sharply higher late Thursday morning, advancing 2.21% to 1,927.62 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion (EVAX), which climbed 14% and 6.9% respectively. They were followed by biotech company BioNTech (BNTX) and biopharmaceutical company DBV Technologies (DBVT), which advanced 4.5% and 4.1% respectively.
The only decliners from continental Europe were telecommunications company Nokia (NOK) and medical device maker EDAP (FOCL), which were down 1% and 0.8% respectively.
The gainers from the UK were led by biopharmaceutical companies Akari Therapeutics (AKTX) and NuCana (NCNA), which rose 8.6% and 6.6% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which were up 4.8% and 3.7% respectively.
The only decliners from the UK and Ireland were biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Amarin (AMRN), which were off 1% and 0.3% respectively.